Showing results (1-10 of 10) with videos related to
Sort By:
Pageof 1
Journal of Biomolecular Screening|May 31, 2015
Discovery of SIRT3 Inhibitors Using SAMDI Mass SpectrometryKaushal Patel, John Sherrill, Milan Mrksich, et al.Traffic (Copenhagen, Denmark)|June 11, 2011
A conserved archaeal pathway for tail-anchored membrane protein insertionJohn Sherrill, Malaiyalam Mariappan, Pawel Dominik, et al.SLAS Discovery : Advancing Life Sciences R & D|June 6, 2017
Identification of Small-Molecule Noncovalent Binders Utilizing SAMDI TechnologyErica C VanderPorten, Michael D Scholle, John Sherrill, et al.Bioorganic & Medicinal Chemistry Letters|February 3, 2005
Synthesis of ring-substituted 4-aminoquinolines and evaluation of their antimalarial activitiesPeter B Madrid, John Sherrill, Ally P Liou, et al.Bioorganic & Medicinal Chemistry|October 12, 2005
Parallel synthesis of 9-aminoacridines and their evaluation against chloroquine-resistant Plasmodium falciparumMarc O Anderson, John Sherrill, Peter B Madrid, et al.Journal of Medicinal Chemistry|January 5, 2007
Structure-activity relationship study of prion inhibition by 2-aminopyridine-3,5-dicarbonitrile-based compounds: parallel synthesis, bioactivity, and in vitro pharmacokineticsBarnaby C H May, Julie A Zorn, Juanita Witkop, et al.Bioorganic & Medicinal Chemistry Letters|July 25, 2006
Structure-activity relationship study of 9-aminoacridine compounds in scrapie-infected neuroblastoma cellsBarnaby C H May, Juanita Witkop, John Sherrill, et al.Journal of Biomolecular Screening|March 11, 2015
A High-Throughput Mass Spectrometry Assay Coupled with Redox Activity Testing Reduces Artifacts and False Positives in Lysine Demethylase ScreeningTim J Wigle, Kerren K Swinger, John E Campbell, et al.Molecular Cancer Therapeutics|November 5, 2021
SAM-Competitive PRMT5 Inhibitor PF-06939999 Demonstrates Antitumor Activity in Splicing Dysregulated NSCLC with Decreased Liability of Drug ResistanceKristen Jensen-Pergakes, John Tatlock, Karen A Maegley, et al.Journal of Medicinal Chemistry|December 7, 2017
Optimization of Orally Bioavailable Enhancer of Zeste Homolog 2 (EZH2) Inhibitors Using Ligand and Property-Based Design Strategies: Identification of Development Candidate (R)-5,8-Dichloro-7-(methoxy(oxetan-3-yl)methyl)-2-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-3,4-dihydroisoquinolin-1(2H)-one (PF-06821497)Pei-Pei Kung, Patrick Bingham, Alexei Brooun, et al.Pageof 1